Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

Riechelmann, Rachel; Srimuninnimit, Vichien; Bordonaro, Roberto; Kavan, Petr; Di Bartolomeo, Maria; Maiello, Evaristo; ÇİÇİN, İRFAN; Garcia-Alfonso, Pilar; Chau, Ian; Fedyanin, Mikhail; Fernandez Martos, Carlos; Ter-Ovanesov, Mikhail; Peeters, Marc; Ko, Yoo-Joung; YALÇIN, ŞUAYİB; Karthaus, Meinolf; Aparicio, Jorge; Heinemann, Volker; Picard, Pascaline; Bury, Denise; Drea, Edward; Sobrero, Alberto

doi:10.1016/j.clcc.2019.05.003

Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

Copy For Citation

Riechelmann R. P., Srimuninnimit V., Bordonaro R., Kavan P., Di Bartolomeo M., Maiello E., ...More

CLINICAL COLORECTAL CANCER, vol.18, no.3, pp.183-194, 2019 (SCI-Expanded)

Publication Type: Article / Article
Volume: 18 Issue: 3
Publication Date: 2019
Doi Number: 10.1016/j.clcc.2019.05.003
Journal Name: CLINICAL COLORECTAL CANCER
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.183-194
Hacettepe University Affiliated: Yes

Abstract

This study evaluated safety and quality of life in patients with metastatic colorectal cancer undergoing treatment with aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan). Most patients treated with this combination experienced either improvement or stability in quality of life scores. Aflibercept plus FOLFIRI is tolerable in the treatment of patients with metastatic colorectal cancer with a safety profile similar to that seen in previous studies of these individual medications.